Your browser doesn't support javascript.
loading
Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination
Lily E. Adams; Sarah R Leist; Kenneth H Dinnon III; Ande West; Kendra L Gully; Elizabeth Anderson; Jennifer F Loome; Emily Madden; John Powers; Alexandra Schaefer; Sanjay Sarkar; Izabella Castillo; Jenny Maron; Ryan P McNamara; Harry L Bertera; Mark R Zweigart; Jaclyn S Higgins; Brea K Hampton; Prem Lakshmanane; Galit Alter; Stephanie Montgomery; Victoria Baxter; Mark T. Heise; Ralph S. Baric.
Afiliação
  • Lily E. Adams; University of North Carolina at Chapel Hill
  • Sarah R Leist; University of North Carolina
  • Kenneth H Dinnon III; University of North Carolina at Chapel Hill
  • Ande West; University of North Carolina at Chapel Hill
  • Kendra L Gully; University of North Carolina
  • Elizabeth Anderson; University of North Carolina
  • Jennifer F Loome; University of North Carolina
  • Emily Madden; University of North Carolina at Chapel Hill
  • John Powers; University of North Carolina at Chapel Hill
  • Alexandra Schaefer; University of North Carolina at Chapel Hill
  • Sanjay Sarkar; University of North Carolina at Chapel Hill
  • Izabella Castillo; The University of North Carolina at Chapel Hill School of Medicine
  • Jenny Maron; Ragon Institute of MGH, MIT, and Harvard University
  • Ryan P McNamara; Ragon Institute of MGH, MIT, and Harvard University
  • Harry L Bertera; Ragon Institute of MGH, MIT, and Harvard University
  • Mark R Zweigart; University of North Carolina
  • Jaclyn S Higgins; University of North Carolina at Chapel Hill
  • Brea K Hampton; University of North Carolina
  • Prem Lakshmanane; University of North Carolina at Chapel Hill
  • Galit Alter; Ragon Institute of MGH, MIT, and Harvard
  • Stephanie Montgomery; Dallas Tissue Research
  • Victoria Baxter; University of North Carolina at Chapel Hill
  • Mark T. Heise; University of North Carolina at Chapel Hill
  • Ralph S. Baric; University of North Carolina at Chapel Hill
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-518175
ABSTRACT
Two group 2B {beta}-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. The mechanisms of cross protection driven by the sarbecovirus spike, a dominant immunogen, are less clear yet critically important for pan-sarbecovirus vaccine development. We evaluated the mechanisms of cross-sarbecovirus protective immunity using a panel of alphavirus-vectored vaccines covering bat to human strains. While vaccination did not prevent virus replication, it protected against lethal heterologous disease outcomes in both SARS-CoV-2 and clade 2 bat sarbecovirus HKU3-SRBD challenge models. The spike vaccines tested primarily elicited a highly S1-specific homologous neutralizing antibody response with no detectable cross-virus neutralization. We found non-neutralizing antibody functions that mediated cross protection in wild-type mice were mechanistically linked to FcgR4 and spike S2-binding antibodies. Protection was lost in FcR knockout mice, further supporting a model for non-neutralizing, protective antibodies. These data highlight the importance of FcR-mediated cross-protective immune responses in universal pan-sarbecovirus vaccine designs.
Licença
cc_no
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Experimental_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Experimental_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
...